# RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing

Study · id `cardio:ct-nct06195540` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06195540](<https://clinicaltrials.gov/study/NCT06195540>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06195540

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1424 participants.

## Technical summary

Registry record NCT06195540. Randomized; single masking; primary purpose prevention. Start 2024-07-19 (actual); primary completion 2028-11-19 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 1424 participants (planned count; ClinicalTrials.gov record NCT06195540, source copy `cardio:ctgov-nct06195540-2026-06-25`, retrieved 2026-10-31)
- Started: 2024-07-19 (actual) (ClinicalTrials.gov record NCT06195540, source copy `cardio:ctgov-nct06195540-2026-06-25`, retrieved 2026-10-31)
- Primary completion: 2028-11-19 (anticipated) (ClinicalTrials.gov record NCT06195540, source copy `cardio:ctgov-nct06195540-2026-06-25`, retrieved 2026-10-31)
- Completion: 2028-11-19 (anticipated) (ClinicalTrials.gov record NCT06195540, source copy `cardio:ctgov-nct06195540-2026-06-25`, retrieved 2026-10-31)
- Countries: France (ClinicalTrials.gov record NCT06195540, source copy `cardio:ctgov-nct06195540-2026-06-25`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06195540-2026-06-25`, retrieved 2026-10-31)

## The registry's words

- Brief title: RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing
- Acronym: RIVACAST
- Condition: Venous Thromboembolism
- Condition: Deep Vein Thrombosis
- Condition: Pulmonary Embolism
- Condition: Lower Limb Trauma
- Condition: Thromboprophylaxis
- Condition: Immobilisation
- Intervention (Drug): Rivaroxaban 10 MG
- Intervention (Drug): Low Heparin Molecular Weight
- Lead sponsor: University Hospital, Angers
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry lists this organization as the lead sponsor: University Hospital, Angers (`cardio:org-university-hospital-angers`)

## Provenance

Content hash: 02252d225a7115c5d0101154769ba08af7e4356e1bb60bc7000940cce165dfe1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
